Mariah
Senior Member
- Messages
- 120
I just have a question regarding the dosage of Rituximab, and was hoping @Jonathan Edwards could answer me.
At Kolibri, the Norwegian clinic that treats ME-patients with Rituximab, the two first doses are at 1 g each with follow up doses at 500 mg. At the Haukeland trials my understanding is that the dosage was determined individually for height and weight. So I was wondering if the differences in dosage, with Kolibri`s being higher, could affect the outcome and the overall respons? I understand that it would certainly affect the amount of side effects and who has an increase in their ME-symptoms, which are far higher at Kolibri than at the trials. But could it also affect the response, could the amount of people responding somehow go down, the response disappear for some who would otherwise respond at a lower dosage, or the response get worse with this increase in dosage? I know this may be a dumb question, but in many other diseases it`s often a question of the right dose rather than the highest dose.
At Kolibri, the Norwegian clinic that treats ME-patients with Rituximab, the two first doses are at 1 g each with follow up doses at 500 mg. At the Haukeland trials my understanding is that the dosage was determined individually for height and weight. So I was wondering if the differences in dosage, with Kolibri`s being higher, could affect the outcome and the overall respons? I understand that it would certainly affect the amount of side effects and who has an increase in their ME-symptoms, which are far higher at Kolibri than at the trials. But could it also affect the response, could the amount of people responding somehow go down, the response disappear for some who would otherwise respond at a lower dosage, or the response get worse with this increase in dosage? I know this may be a dumb question, but in many other diseases it`s often a question of the right dose rather than the highest dose.